A personalised vaccine against melanoma can more than double the survival
rate for patients with the advanced form of this skin cancer. Doctors at
Jefferson Medical College in Philadelphia create customised vaccines from
patients’ own cancer cells by inactivating them and altering their surface
proteins with dinitrophenol. Five-year survival rates in 214 patients with
advanced disease increased from around 20 per cent to 50 per cent and a
randomised phase III trial of 400 patients across the US is planned.
More from New Scientist
Explore the latest news, articles and features
Technology
Test moderators use AI-generated writing to judge literacy standards
News
Mind
THC in cannabis may reduce nightmares in people with PTSD
News
Environment
Fishers detonate a bomb every hour on one Indonesian coral reef
News
Environment
How bad is the UK drought and how long will it continue?
News
Popular articles
Trending New Scientist articles